Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC.

Becker D, Sfakianakis I, Krupp M, Staib F, Gerhold-Ay A, Victor A, Binder H, Blettner M, Maass T, Thorgeirsson S, Galle PR, Teufel A.

Mol Cancer. 2012 Aug 14;11:55. doi: 10.1186/1476-4598-11-55.

2.
3.

Identifying hub genes and dysregulated pathways in hepatocellular carcinoma.

Jin B, Wang W, Du G, Huang GZ, Han LT, Tang ZY, Fan DG, Li J, Zhang SZ.

Eur Rev Med Pharmacol Sci. 2015 Feb;19(4):592-601.

4.

Early molecular and genetic determinants of primary liver malignancy.

Feitelson MA, Pan J, Lian Z.

Surg Clin North Am. 2004 Apr;84(2):339-54. Review.

PMID:
15062649
5.

CellMinerHCC: a microarray-based expression database for hepatocellular carcinoma cell lines.

Staib F, Krupp M, Maass T, Itzel T, Weinmann A, Lee JS, Schmidt B, Müller M, Thorgeirsson SS, Galle PR, Teufel A.

Liver Int. 2014 Apr;34(4):621-31. doi: 10.1111/liv.12292. Epub 2013 Sep 9.

PMID:
24016071
6.

Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma.

De Giorgi V, Monaco A, Worchech A, Tornesello M, Izzo F, Buonaguro L, Marincola FM, Wang E, Buonaguro FM.

J Transl Med. 2009 Oct 12;7:85. doi: 10.1186/1479-5876-7-85.

7.

Gene expression profiling of liver cancer stem cells by RNA-sequencing.

Ho DW, Yang ZF, Yi K, Lam CT, Ng MN, Yu WC, Lau J, Wan T, Wang X, Yan Z, Liu H, Zhang Y, Fan ST.

PLoS One. 2012;7(5):e37159. doi: 10.1371/journal.pone.0037159. Epub 2012 May 14.

8.

Comparative and integrative functional genomics of HCC.

Lee JS, Thorgeirsson SS.

Oncogene. 2006 Jun 26;25(27):3801-9. Review.

PMID:
16799621
9.

Comparison of pathways associated with hepatitis B- and C-infected hepatocellular carcinoma using pathway-based class discrimination method.

Lee SY, Song KH, Koo I, Lee KH, Suh KS, Kim BY.

Genomics. 2012 Jun;99(6):347-54. doi: 10.1016/j.ygeno.2012.04.004. Epub 2012 Apr 29.

10.

Molecular signatures and prognosis of hepatocellular carcinoma.

Hoshida Y.

Minerva Gastroenterol Dietol. 2011 Sep;57(3):311-22.

PMID:
21769080
11.

Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray.

Liu Y, Zhu X, Zhu J, Liao S, Tang Q, Liu K, Guan X, Zhang J, Feng Z.

Oncol Rep. 2007 Oct;18(4):943-51.

PMID:
17786358
12.

Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma.

Qiu W, David D, Zhou B, Chu PG, Zhang B, Wu M, Xiao J, Han T, Zhu Z, Wang T, Liu X, Lopez R, Frankel P, Jong A, Yen Y.

Am J Pathol. 2003 Jun;162(6):1961-74.

13.

Clinicopathologic and gene expression parameters predict liver cancer prognosis.

Hao K, Lamb J, Zhang C, Xie T, Wang K, Zhang B, Chudin E, Lee NP, Mao M, Zhong H, Greenawalt D, Ferguson MD, Ng IO, Sham PC, Poon RT, Molony C, Schadt EE, Dai H, Luk JM.

BMC Cancer. 2011 Nov 9;11:481. doi: 10.1186/1471-2407-11-481.

14.

Integrative genomics: liver regeneration and hepatocellular carcinoma.

Coban Z, Barton MC.

J Cell Biochem. 2012 Jul;113(7):2179-84. doi: 10.1002/jcb.24104.

15.

Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.

Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S, Yamada T.

Clin Cancer Res. 2010 May 1;16(9):2518-28. doi: 10.1158/1078-0432.CCR-09-2214. Epub 2010 Apr 13.

16.

Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma.

Wang SM, Ooi LL, Hui KM.

Clin Cancer Res. 2011 Sep 15;17(18):6040-51. doi: 10.1158/1078-0432.CCR-11-0557. Epub 2011 Aug 8.

17.

Identification of hepatocellular carcinoma-associated hub genes and pathways by integrated microarray analysis.

Liu F, Li H, Chang H, Wang J, Lu J.

Tumori. 2015 Mar-Apr;101(2):206-14. doi: 10.5301/tj.5000241. Epub 2015 Mar 13.

PMID:
25768320
18.

Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease.

Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, Frau M, Tomasi ML, De Miglio MR, Seddaiu MA, Daino L, Sanna V, Feo F, Pascale RM.

Carcinogenesis. 2008 Aug;29(8):1639-47. doi: 10.1093/carcin/bgn155. Epub 2008 Jun 25.

PMID:
18579559
19.
20.

Proliferative drive and liver carcinogenesis: too much of a good thing?

Teoh NC.

J Gastroenterol Hepatol. 2009 Dec;24(12):1817-25. doi: 10.1111/j.1440-1746.2009.06121.x. Review.

PMID:
20002941

Supplemental Content

Support Center